Citations

Clear

3030 citation(s) found for "Susan, M".

INNV-28. MOLECULAR TESTING IN NEURO-ONCOLOGY – ASSESSMENT OF UTILITY AND PRACTICE PATTERNS. A SOCIETY FOR NEURO-ONCOLOGY MEMBERSHIP SURVEY
Mrugała, Maciej M. , Chang, Susan M.

Mayo Clinic

Neuro-Oncology | November 11, 2019 | Volume: 21 | Issue: Supplement_6 | Pages: vi136-vi136

10.1093/neuonc/noz175.569 Get It

Abstract BACKGROUND Molecular testing (MT) is utilized in neuro-oncology with increasing frequency. Multiple molecular panels are available providing a spectrum of information. We were interested in learning how this information is acquired, what are the practice patterns regarding this type of testing, how are the results utilized in patient care and how prepared neuro-oncologists are to interpret these results. METHODS We conducted a survey using the Society for Neuro-Oncology membership database. We developed a set of 13 questions and administered the survey to 2022 members using the online platform. RESULTS We received 153 responses (7.5% of membership). 89% percent of responders routinely order MT. Of those who do not order MT on all patients, 50% test younger patients and 57% midline tumors. 83% use MT in recurrent glioma. Other common indications for MT included: metastatic tumors, meningioma, medulloblastoma, ATRT. Majority (60%) use in-house panels, followed by Foundation One (35%), TEMPUS (13%), CARIS (10%) and other panels (23%). For 57% of respondents, the data from MT was somewhat useful and for 41% it was very useful. 78% used the results of MT for clinical decision-making. BRAF, EGFR/ALK, H3K27 mutations were most commonly used for treatment decisions. 50% of respondents have molecular tumor boards at their institutions and a majority of practitioners share the results of MT with their patients (95%). Respondents would like to see SNO-endorsed official guidelines on MT, organized lists of targeted agents available for specific mutations, a database of targetable mutations and clinical trials and more educational programs on the subject. CONCLUSIONS Molecular testing is neuro-oncology is commonly done. Many providers rely on the information for clinical decision making where appropriate. In-house and commercial genetic panels are equally used in practice. There continues to be a need for more education on the subject and development of neuro-oncology specific guidelines.
DRES-12. QUANTIFYING INDIVIDUALIZED ABT-414 SENSITIVITY AND BLOOD-BRAIN BARRIER PENETRANCE FROM SERIAL IMAGING OF PATIENT-DERIVED XENOGRAFTS MODELS OF GLIOBLASTOMA
Urcuyo, Javier , Marin, Bianca M. , Swanson, Kristin R. , Swanson, Kristin R , Marin, Bianca M , Massey, Susan Christine , Sarkaria, Jann N.

Mayo Clinic

Neuro-Oncology | November 11, 2019 | Volume: 21 | Issue: Supplement_6 | Pages: vi73-vi74

10.1093/neuonc/noz175.299 Get It

Abstract INTRODUCTION Glioblastoma (GBM) is an aggressive primary brain tumor, known for its poor prognosis. Due to its diffuse invasiveness into normal-appearing brain, localized treatments such as surgical resection and radiotherapy are typically supplemented with chemotherapy. However, to reach invading tumor cells, such antineoplastic drugs must cross the blood-brain barrier (BBB). That is, while angiogenesis induces BBB breakdown in dense tumor regions, the BBB remains rather intact for invading GBM cells. As a result, it is unclear whether BBB-impermeable drugs are delivered at a sufficient level to be effective. METHODS In order to study heterogeneity in BBB breakdown, experiments were conducted using both flank and intracranial patient-derived xenografts (PDXs) treated with the EGFR-targeted monoclonal antibody drug conjugate, depatuxizumab mafodotin (ABT-414). Time-series bioluminescence imaging (BLI) data was used to develop a differential equation model of tumor growth for three PDX cell lines. Data from untreated PDXs, both in flank and intracranially, were used to parameterize tumor proliferation rates. Flank PDX data were used to parameterize individual sensitivity to ABT-414, whereas intracranial PDX data were used to determine the proportion of drug exposed to the tumor. RESULTS Each PDX line differed in response to the study drug ABT-414. As expected, such heterogeneous responses can primarily be attributed to differences in both drug sensitivity and the proportion of drug that reached the tumor. Notably, the estimated proportion of drug that reached the tumor was highest in the PDX line with the longest survival times, despite also having higher estimates of resistance. This suggests that PDXs with greater overall BBB breakdown may respond better to this agent. CONCLUSIONS Although more cell lines are needed to validate our approach, parameterizing this model for PDXs gives valuable insight into the extent of BBB breakdown in patient GBMs and may aid in determining optimal therapies for individual patients.
INNV-33. BARRIERS TO ACCRUAL AND ENROLLMENT IN BRAIN TUMOR TRIALS
Lee, Eudocia Q. , Chukwueke, Ugonma , Hervey‐Jumper, Shawn L. , DeGroot, John, Leone, Pablo, Chang, Susan M. , Arons, David, Oliver, Kathy , Verble, Kay, Musella, Al , Willmarth, Nicole E. , Doherty, Lisa, Gaffey, Sarah, Halkin, Thomas, Friday, Bret Edward Buckley, Fouladi, Maryam , Macdonald, David R., Peñas-Prado, Marta , Vogelbaum, Michael A. , Sahebjam, Solmaz , Sandak, David, Reardon, David A. , Wen, Patrick Y. , Armstrong, Terri S. , Alexander, Brian M. , Bates, Amanda, Galanis, Evanthia , Lin, Nancy U. , Mehta, Minesh P. , Bent, Martin J. van den , Weller, Michael , Wen, Patrick Yung

Mayo Clinic

Neuro-Oncology | November 11, 2019 | Volume: 21 | Issue: Supplement_6 | Pages: vi137-vi137

10.1093/neuonc/noz175.574 Get It

Abstract BACKGROUND A major impediment to improving neuro-oncology outcomes is poor clinical trial accrual. METHODS We convened a multi-stakeholder group including Society for Neuro-Oncology, Response Assessment in Neuro-Oncology, patient advocacy groups, clinical trial cooperative groups, and other partners to determine how we can improve trial accrual. RESULTS We described selected factors contributing to poor trial accrual and possible solutions. We focused on patient and community factors, disparities, physician and provider factors, clinical trial factors, and site and organizational factors CONCLUSIONS We will implement strategies with the intent to double accrual to neuro-oncology trials over the next 5 years.
DUAL DECLINE IN MEMORY AND GAIT UNIQUELY IDENTIFIES OLDER PERSONS AT HIGH RISK OF DEMENTIA
Resnick, Susan M. , Yaffe, Kristine , Studenski, Stephanie, Tian, Qu , Mielke, Michelle M. , Rosano, Caterina , Simonsick, Eleanor Marie , Studenski, Stephanie A. , Ferrucci, Luigi

Mayo Clinic

Innovation in Aging | November 9, 2019 | Volume: 3 | Issue: Supplement_1 | Pages: S586-S586

10.1093/geroni/igz038.2173 Get It

Abstract Recent study has shown that incident dementia risk is higher among older persons who decline in both cognition and gait. This study assesses whether this relationship exists in multiple other aging populations. Data are from the Baltimore Longitudinal Study of Aging (n=662, 51%women,22%blacks), Health, Aging and Body Composition Study (n=746, 51%women,44%blacks), and Mayo Clinic Study of Aging (n=2771, 48%women,0.3%blacks). Participants were at least 60, initially free of cognitive impairment, dementia, and dismobility (gait speed≤0.6m/s), with repeated measures of verbal memory and gait speed before dementia diagnosis (average follow-up 5.8-12.1 years). Within each cohort, participants were divided into four groups: memory decliners alone, gait decliners alone, dual decliners, or neither (healthy agers). Gait speed decline was defined as a loss of ≥0.05m/sec/year; memory decline was defined as cohort specific bottom slope tertile. Incident dementia risk was examined by Cox regression with healthy agers as reference, adjusted for sex, race, baseline age, gait speed and memory. Across studies, incident dementia ranged from 3% to 17%. Compared to healthy agers, memory decliners alone had 3.4 to 4.3 times higher risk for developing dementia (p<0.01). Gait decliners alone had 2.1-5.6 times higher risk for dementia (p<0.05). Dual decliners had 7.6-10.8 times the risk (p<0.001). Dual decline signifies a more rapid progression to dementia. These consistent findings suggest that dual decliners might be a potentially valuable target group for both preventive interventions and mechanistic studies. Whether dual decline identifies a particular subtype or multiple subtypes of dementia remains to be investigated.
Pain medicine fellow neuromodulation surgical skill assessment tool: a pilot
Pittelkow, Thomas P. , Hagedorn, Jonathan M. , Bendel, Markus A. , Eldrige, Jason S. , Pingree, Matthew J. , Mauck, William D. , Gazelka, Halena M. , Lamer, Tim J. , Sanders, Rebecca A., Billinges, Heather A, Moeschler, Susan M. , Billings, Heather , Mauck, W David, Pittelkow, Thomas P , Hagedorn, Jonathan M , Billings, Heather

Mayo Clinic

Regional Anesthesia & Pain Medicine | November 6, 2019 | Volume: 45 | Issue: 1 | Pages: 38-43

10.1136/rapm-2019-100761 | PMID 31694935 Get It

Objective Spinal cord stimulation (SCS) is an evidence-based therapy for the treatment of refractory pain. Current American College of Graduate Medical Education requirements for pain medicine fellowship graduation include observation of five neuromodulation cases. Matriculating fellows have varying degrees of technical skill, training, and experience. The purpose of this study was to use an innovative skill-based assessment tool using the validated Zwisch scale to evaluate fellow surgical performance during SCS cases. Design Cross-sectional survey Setting Mayo Clinic, Rochester, Minnesota. Subjects Consultant faculty (10) in the Division of Pain Medicine and pain medicine fellows (5). Methods A list of faculty-driven neuromodulation surgical objectives was formed and a rubric was created that focused on technical approach, imaging, epidural access and wound closure. Consultants who perform surgical cases were instructed to use the Zwisch scale as a guide to evaluate fellow surgical performance during a neuromodulation case. Faculty and fellows were surveyed before and after implementation of the tool to determine their satisfaction with use of the skill assessment tool. Results The consultants reported they were more satisfied, consistent, and efficient with feedback provided to the trainee on every aspect of neuromodulation surgical cases. The improvement was most significant during the fellows’ intraoperative skill assessment. The fellows indicated increased satisfaction, improved communication, and increased efficiency of feedback when the tool was utilized. The fellows reported greater intraoperative skill assessment and consistency of feedback provided. Conclusions The diverse nature of primary specialty backgrounds observed in pain medicine fellowship training offers a unique opportunity to assess and improve fellow skill and surgical competence in the field of neuromodulation. Both faculty and fellows reported improved satisfaction, consistency and efficiency with feedback provided. Importantly, this pilot project observed that implementation of a skill assessment tool was beneficial for both the faculty and fellow as the feedback received was viewed as strongly beneficial to the educational experience.
Representation of Women Among Invited Speakers at Medical Specialty Conferences
Sharkey, Katherine M. , Poorman, Julie A., Kan, Carolyn , Moeschler, Susan M. , Chandrabose, Rekha K. , Marquez, Carol, Dodge, Daleela , Nazarian, Rosalynn M. , Larson, Allison R , Silver, Julie K.

Mayo Clinic

Journal of Women's Health | November 5, 2019 | Volume: 29 | Issue: 4 | Pages: 550-560

10.1089/jwh.2019.7723 | PMID 31687866 Get It

TBCRC023: A Randomized Phase II Neoadjuvant Trial of Lapatinib Plus Trastuzumab Without Chemotherapy for 12 versus 24 Weeks in Patients with HER2-Positive Breast Cancer
Rimawi, Mothaffar F. , Rexer, Brent N. , Forero, Andres , Wolff, Antonio C. , Nanda, Rita , Storniolo, Anna Maria , Krop, Ian E. , Nangia, Julie R. , Jiralerspong, Sao , Pavlick, Anne C. , Veeraraghavan, Jamunarani , Angelis, Carmine De , Osborne, C. Kent , Wang, Tao , Wolff, Antonio C , Schiff, Rachel , Hilsenbeck, Susan Galloway , Rimawi, Mothaffar , De Angelis, Carmine , Niravath, Polly Ann , Wang, Tao , Goetz, Matthew P. , Gutiérrez, Carolina , Schiff, Rachel

Mayo Clinic

Clinical Cancer Research | October 29, 2019 | Volume: 26 | Issue: 4 | Pages: 821-827

10.1158/1078-0432.ccr-19-0851 | PMID 31662331 Get It

Abstract Purpose: Prior neoadjuvant trials with 12 weeks of dual anti-HER2 therapy without chemotherapy demonstrated a meaningful pathologic complete response (pCR) in patients with HER2-positive breast cancer. In this trial, we sought to determine whether longer treatment would increase the rate of pCR. Patients and Methods: TBCRC023 (NCT00999804) is a randomized phase II trial combining a Simon phase II design in the experimental arm with a pick-the-winner design, not powered for direct comparison. Women with HER2-positive breast tumors measuring ≥2 cm (median = 5 cm) were randomized in a 1:2 ratio to 12 versus 24 weeks of lapatinib and trastuzumab. Letrozole (along with ovarian suppression if premenopausal) was administered in patients whose tumors were also estrogen receptor (ER) positive. All evaluable patients were assessed for in-breast pCR. Results: Ninety-seven patients were enrolled (33 in 12-week arm and 64 in 24-week arm), of whom 94 were evaluable. Median age was 51 years, and 55% were postmenopausal. Median tumor size was 5 cm, and 65% were ER-positive. The rate of pCR in the 24-week arm was 28% and numerically superior to the 12-week arm (12%). This was driven by increased pCR in the ER-positive subgroup (33% vs. 9%). Study treatment was well tolerated, with grade 1–2 diarrhea and acneiform rash being the most common toxicities. Conclusions: Treatment with dual anti-HER2 therapy for 24 weeks led to a numeric increase in pCR rate in women with HER2-positive breast cancer, without using chemotherapy. If validated, this approach may help identify patients who may benefit from deescalation of therapy.
322.5: Impact of a face procurement on intermediate solid organ outcomes.
Rogers, Meg, Amer, Hatem , Gunderson, Susan, Amer, Hatem , Mardini, Samir

Mayo Clinic

Transplantation | October 25, 2019 | Volume: 103 | Issue: 11S | Pages: S69-S69

10.1097/01.tp.0000611944.00511.3d Get It

Efficacy and tolerability of adjunctive modafinil/armodafinil in bipolar depression: A meta‐analysis of randomized controlled trials
Núñez, Nicolás A. , Singh, Balwinder , Romo‐Nava, Francisco , Joseph, Boney , Cuéllar‐Barboza, Alfredo B. , Cabello-Arreola, Alejandra , Voort, Jennifer L. Vande , Moore, Katherine M. , Frye, Mark A. , Cuellar-Barboza, Alfredo , Cabello Arreola, Alejandra, Vande Voort, Jennifer L., Croarkin, Paul, Biernacka, Joanna , Romo-Nava, F , Singh, Balwinder , Joseph, Boney , Veldić, Marin , Croarkin, Paul E. , Biernacka, Joanna M. , McElroy, Susan L.

Mayo Clinic

Bipolar Disorders | October 23, 2019 | Volume: 22 | Issue: 2 | Pages: 109-120

10.1111/bdi.12859 | PMID 31643130 Get It

Abstract Objective The aim of this study was to evaluate the efficacy and safety of the dopaminergic‐enhancing agent modafinil/armodafinil (MoArm) as adjunctive treatment for bipolar depression. Methods A comprehensive search of major electronic databases was conducted to identify randomized controlled trials (RCTs) of adjunctive MoArm that included patients with bipolar I (BP‐I) or bipolar II (BP‐II) depression. Data for response/remission and all‐cause discontinuation were analyzed. Effect size was summarized by relative risk (RR) using a random effect model. Results Of 58 studies, five RCTs (N = 795 drug, N = 792 placebo) met inclusion criteria. Four armodafinil studies included only BP‐I patients and one modafinil study included both bipolar subtypes with limited heterogeneity ( I 2 = 34%, P = .19; I 2 = 18%, P = .30). Compared to placebo, augmentation with MoArm was associated with significantly greater rates of treatment response (RR, 1.18; 95% CI, 1.01‐1.37; P = .03) and remission (RR, 1.38; 95% CI, 1.10‐1.73; P = .005). All‐cause discontinuation was not different than placebo (RR, 1.08; 95% CI, 0.89‐1.30; P = .45) with no evidence of increased risk of mood switch or suicide attempts with MoArm (RR, 0.99; 95% CI, 0.39‐2.5; P = .98; RR, 1.02; 95% CI, 0.37‐2.85; P = .97). Conclusion This narrower scope meta‐analysis of one drug for one disease suggests that adjunctive MoArm may represent a novel therapeutic intervention. Further studies delineating the subtypes of bipolar depression responsive to these novel dopaminergic‐enhancing agents are encouraged.
The Impact of Urban Zen Integrative Therapy on Symptoms and Health-Related Quality of Life for Patients with Pulmonary Hypertension
Visger, Tania Von , Klatt, Maryanna , Dabbs, Annette DeVito , Tan, Alai , Happ, Mary Beth , Thrane, Susan E. , Chlan, Linda L.

Mayo Clinic

Journal of Palliative Medicine | October 23, 2019 | Volume: 23 | Issue: 5 | Pages: 703-711

10.1089/jpm.2019.0359 | PMID 31644380 Get It

Background: Patients with pulmonary hypertension (PH) experience distressing symptoms that can undermine quality of life (QoL) and treatment adherence. Complementary health approaches are known to help manage symptoms of chronic conditions and may have therapeutic benefits in PH. Objective: To explore the impact of Urban Zen Integrative Therapy (UZIT) on PH-related symptoms. Design: A within-subjects, pre-/post-intervention, repeated-measures design. Subjects/Setting: Community-dwelling adults with PH received weekly UZIT sessions in an outpatient setting. Measurements: Participants ( n = 14) rated symptoms before and after each session and before and after the six-week UZIT program. Mixed-effects modeling with repeated measures was used to estimate differences in mean symptom scores before and after individual sessions. Cohen's d effect sizes were used to evaluate the impact of the UZIT program on symptoms. Results: Mean scores for pain ( F (1, 105) = 19.99, p < 0.001), anxiety ( F (1, 96) = 24.64, p < 0.001), fatigue ( F (1, 120) = 15.68, p < 0.001), and dyspnea ( F (1, 68) = 16.69, p < 0.001) were significantly reduced after UZIT sessions. Effects were moderate to large for symptom severity ( d = 0.59–1.32) and moderate for symptom burden ( d = 0.56) and fatigue ( d = 0.62), and small for QoL ( d = 0.33) after the six-week UZIT program. Conclusions: Individualized UZIT sessions were associated with reductions in symptom severity for pain, anxiety, fatigue, and dyspnea. The six-week UZIT program was associated with improvements in symptom burden, activity limitation, and QoL. ClinicalTrial.gov no.: NCT03194438